SBIR/STTR Research Award
Leveraging an academic-industry partnership to develop a cancer-specific mobile meditation app
Award amount
$397,657Program and phase
STTR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Calm.com, Inc.
- Proposal award date
- 2021-03-01
- Contract end date
- 2022-02-28
- UEI
- VM6UCM8BSQ37
- Solicitation number
- PA20-261
- Topic code
- 102
Research abstract
1 Project Summary/Abstract2 Approximately 15.5 million US cancer patients/survivors experience a host of residual symptoms (e.g.,3 fatigue, anxiety, depression, pain, sleep disturbance) and reduced quality of life that are often not resolved with4 even the best-available current standard of care therapies. Residual symptom burden impairs cancer survivor5 functioning and leads to increased rates of disability and healthcare utilization, costing $125 billion every year.6 Cancer patients/survivors want and need complementary strategies to accompany standard therapies.7 Research has demonstrated the benefits of mindfulness-based therapies, such as meditation, for8 alleviating cancer-related symptoms (e.g., fatigue, anxiety, depression, and sleep disturbance).Meditation-based9 programs are typically conducted in-person, in clinic settings; however, these programs are expensive and
10 difficult to sustain, and cancer patients report barriers to participating (e.g., travel demands, fatigue, pain, and
11 scheduling difficulties). Smartphone-based meditation is a feasible and novel method for delivering meditation
12 to cancer patients/survivors. Mobile apps and online meditation programs have demonstrated short-term benefits
13 for cancer patients/survivors; however, the currently available commercial meditation apps are limited in their
14 engagement, acceptability, and applicability to cancer patients/survivors’ unique experiences and have not been
15 evaluated for feasibility or efficacy. There is an unmet need for a commercially-available, evidence-based
16 meditation app specifically designed for cancer patients/survivors. Incorporating stakeholder feedback (i.e.,
17 patients and healthcare providers) in the early design phase will facilitate the development of a meditation app
18 truly targeted for the end users that can be made commercially available, thereby improving uptake and impact
19 in patient populations. Calm, a popular consumer-based meditation app with 70 million downloads and 2 million
20 subscribers, provides a platform from which to develop an accessible standalone cancer-specific meditation app.
21 This project will: 1) gather feedback about the current Calm app from an advisory committee (N=20) consisting
22 of cancer patients/survivors (n=10, 5 of each) and healthcare providers (n=10), 2) design a cancer-specific
23 meditation app prototype, and 3) beta-test the prototype in cancer patients/survivors (N=30).
24 A standalone meditation app designed for and tested by cancer patients/survivors, leveraging a popular
25 and validated meditation app platform, to be made commercially available, is innovative and could provide a
26 scalable, highly engaging symptom-management tool that addresses cancer patients/survivors’ unique needs.
27 If our key feasibility milestones are met, we will further refine the cancer-specific app and conduct a randomized
28 controlled trial to determine the app’s long-term efficacy in reducing symptom burden in cancer patients/survivors
29 (Phase 2) that can later be commercialized and marketed to cancer patients/survivors, healthcare providers, and
30 clinics. (Phase 3).Project Narrative
Currently, there are NO commercially available, evidence-based meditations apps specifically designed for
cancer patients/survivors. The proposed project will leverage an existing consumer-based mobile app, Calm, to
develop a standalone cancer-specific meditation app. We will use our formative work, the social cognitive theory,
and perspectives from a cancer experienced advisory committee to inform the development of the app prototype,
which will then be beta-tested in a second sample of cancer patients/survivors, and later tested for its long-term
efficacy in a randomized controlled trial to make commercially available to cancer populations.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer